{"organizations": [], "uuid": "cba7ee301a998935b8e2200265fdffe5c88717a1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/ip-patent-helsinn/helsinn-urges-scotus-to-define-drugs-on-sale-bar-in-pivotal-case-against-teva-idUSL2N1QJ00W", "country": "US", "domain_rank": 408, "title": "Helsinn urges SCOTUS to define drugs’ on-sale bar in pivotal case against Teva", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.044, "site_type": "news", "published": "2018-03-01T08:23:00.000+02:00", "replies_count": 0, "uuid": "cba7ee301a998935b8e2200265fdffe5c88717a1"}, "author": "Jan Wolfe", "url": "https://www.reuters.com/article/ip-patent-helsinn/helsinn-urges-scotus-to-define-drugs-on-sale-bar-in-pivotal-case-against-teva-idUSL2N1QJ00W", "ord_in_thread": 0, "title": "Helsinn urges SCOTUS to define drugs’ on-sale bar in pivotal case against Teva", "locations": [], "entities": {"persons": [{"name": "helsinn", "sentiment": "negative"}], "locations": [{"name": "aloxi", "sentiment": "none"}], "organizations": [{"name": "helsinn healthcare sa", "sentiment": "negative"}, {"name": "teva", "sentiment": "negative"}, {"name": "u.s. supreme court", "sentiment": "negative"}, {"name": "westlaw", "sentiment": "none"}, {"name": "u.s. federal circuit court of appeals", "sentiment": "none"}, {"name": "teva pharmaceutical industries ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "The pharmaceutical company Helsinn Healthcare SA on Wednesday asked the U.S. Supreme Court to reverse a lower court decision that cleared the way for a generic version of its chemotherapy-induced nausea treatment Aloxi to hit the market.\nHelsinn filed a petition asking the high court to review a May 2017 decision by the U.S. Federal Circuit Court of Appeals that invalidated its patents on Aloxi at the request of Teva Pharmaceutical Industries Ltd based on the “on-sale bar,” a provision of patent law that states an invention cannot be patented if it has been on sale for more than a year before the patent application is filed.\nTo read the full story on Westlaw Practitioner Insights, click here: bit.ly/2FehN39\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2FehN39"], "published": "2018-03-01T08:23:00.000+02:00", "crawled": "2018-03-01T21:08:07.034+02:00", "highlightTitle": ""}